• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Comput Biol Med . Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycopr

tetano

Editor, Senior Moderator
Comput Biol Med


. 2020 Aug 13;124:103967.
doi: 10.1016/j.compbiomed.2020.103967. Online ahead of print.
Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein


Ahmed Rakib[SUP] 1 [/SUP], Saad Ahmed Sami[SUP] 1 [/SUP], Nusrat Jahan Mimi[SUP] 1 [/SUP], Md Mustafiz Chowdhury[SUP] 1 [/SUP], Taslima Akter Eva[SUP] 1 [/SUP], Firzan Nainu[SUP] 2 [/SUP], Arkajyoti Paul[SUP] 3 [/SUP], Asif Shahriar[SUP] 4 [/SUP], Abu Montakim Tareq[SUP] 5 [/SUP], Nazim Uddin Emon[SUP] 5 [/SUP], Sajal Chakraborty[SUP] 6 [/SUP], Sagar Shil[SUP] 6 [/SUP], Sabrina Jahan Mily[SUP] 7 [/SUP], Taibi Ben Hadda[SUP] 8 [/SUP], Faisal A Almalki[SUP] 9 [/SUP], Talha Bin Emran[SUP] 10 [/SUP]



Affiliations

Abstract

Aims: With a large number of fatalities, coronavirus disease-2019 (COVID-19) has greatly affected human health worldwide. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes COVID-19. The World Health Organization has declared a global pandemic of this contagious disease. Researchers across the world are collaborating in a quest for remedies to combat this deadly virus. It has recently been demonstrated that the spike glycoprotein (SGP) of SARS-CoV-2 is the mediator by which the virus enters host cells.
Main methods: Our group comprehensibly analyzed the SGP of SARS-CoV-2 through multiple sequence analysis and a phylogenetic analysis. We predicted the strongest immunogenic epitopes of the SGP for both B cells and T cells.
Key findings: We focused on predicting peptides that would bind major histocompatibility complex class I. Two optimal epitopes were identified, WTAGAAAYY and GAAAYYVGY. They interact with the HLA-B*15:01 allele, which was further validated by molecular docking simulation. This study also found that the selected epitopes are able to be recognized in a large percentage of the world's population. Furthermore, we predicted CD4[SUP]+[/SUP] T-cell epitopes and B-cell epitopes.
Significance: Our study provides a strong basis for designing vaccine candidates against SARS-CoV-2. However, laboratory work is required to validate our theoretical results, which would lay the foundation for the appropriate vaccine manufacturing and testing processes.

Keywords: COVID-19; Epitope; Immunoinformatics; SARS-CoV-2; Spike glycoprotein.
 
Back
Top Bottom